Grail, Inc. (GRAL)
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL partners with Epic to embed its Galleri cancer test into EHRs, expanding access across nearly 450 health systems and streamlining clinical workflows nationwide.
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
GRAIL, Inc. (NASDAQ:GRAL) Receives Consensus Recommendation of “Hold” from Analysts
Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) have received a consensus recommendation of "Hold" from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the
Grail CEO Bob Ragusa to retire, Josh Ofman named successor
Cancer test maker Grail said on Thursday that chief executive Bob Ragusa will retire effective June 1, and the company's president, Josh Ofman, will take over the helm.
'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection
A T206 Honus Wagner baseball card in a family collection for 116 years was sold for $5.124 million at auction, becoming the third-most expensive ever for this specific card.
Biotech Stock Plummets on Cancer Screening Trial Results
Biotech stock Grail Inc (NASDAQ:GRAL) is taking a nosedive today, brushing off better-than-expected fourth-quarter results after the company's three-year cancer screening trial failed to meet its main goal.
Grail shares plunge after major cancer screening trial misses main goal
Grail shares plunged nearly 50% in premarket trading on Friday after its three-year cancer screening trial failed to meet its main goal, dealing a major blow to the blood test maker.
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test
GRAL submits final FDA PMA module for the Galleri MCED test, reaching a milestone in broader cancer screening and potential public health impacts.
GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
